lansoprazole has been researched along with Alzheimer Disease in 5 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "His only medical history was mild Alzheimer's disease diagnosed 6 months prior." | 2.52 | Upper gastrointestinal bleed associated with cholinesterase inhibitor use. ( Kok, KS; Loke, Y; Southgate, J, 2015) |
| "A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases." | 1.39 | The proton-pump inhibitor lansoprazole enhances amyloid beta production. ( Alcalde, V; Aloy, P; Badiola, N; Coma, M; Lleó, A; Multhaup, G; Münter, LM; Pujol, A; Soler-López, M, 2013) |
| "Lansoprazole treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations." | 1.39 | Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. ( Singh, N; Sodhi, RK, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badiola, N | 1 |
| Alcalde, V | 1 |
| Pujol, A | 1 |
| Münter, LM | 1 |
| Multhaup, G | 1 |
| Lleó, A | 1 |
| Coma, M | 1 |
| Soler-López, M | 1 |
| Aloy, P | 1 |
| Sodhi, RK | 1 |
| Singh, N | 1 |
| Fawaz, MV | 1 |
| Brooks, AF | 1 |
| Rodnick, ME | 1 |
| Carpenter, GM | 1 |
| Shao, X | 1 |
| Desmond, TJ | 1 |
| Sherman, P | 1 |
| Quesada, CA | 1 |
| Hockley, BG | 1 |
| Kilbourn, MR | 1 |
| Albin, RL | 1 |
| Frey, KA | 1 |
| Scott, PJ | 1 |
| Kok, KS | 1 |
| Loke, Y | 1 |
| Southgate, J | 1 |
| Rojo, LE | 1 |
| Alzate-Morales, J | 1 |
| Saavedra, IN | 1 |
| Davies, P | 1 |
| Maccioni, RB | 1 |
1 review available for lansoprazole and Alzheimer Disease
| Article | Year |
|---|---|
Upper gastrointestinal bleed associated with cholinesterase inhibitor use.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Duodenal Ulcer; Endoscop | 2015 |
4 other studies available for lansoprazole and Alzheimer Disease
| Article | Year |
|---|---|
The proton-pump inhibitor lansoprazole enhances amyloid beta production.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alzheimer Disease; Amyloid beta-Peptides; Animals; CHO Cell | 2013 |
Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet.
Topics: Acetylcholinesterase; Alzheimer Disease; Analysis of Variance; Animals; Body Weight; Brain; Choleste | 2013 |
High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Autoradiography; Brain; Carbon Radioisotopes; Dru | 2014 |
Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alzheimer Disease; Astemizole; Brain; Chromatography, High | 2010 |